Ozawa H, Kawashima I, Tai T
Department of Tumor Immunology, Tokyo Metropolitan Institute of Medical Science, Honkomagome, Japan.
Arch Biochem Biophys. 1992 May 1;294(2):427-33. doi: 10.1016/0003-9861(92)90707-4.
We generated two murine monoclonal antibodies (MAbs) specific for mono- and disialylgangliosides having N-glycolylneuraminic acid (NeuGc) as their sialic acid moiety, respectively, by immunizing C3H/HeN mice with these purified gangliosides adsorbed to Salmonella minnesota followed by fusion with mouse myeloma cells. By use of a wide variety of glycolipids, including NeuGc-containing gangliosides, the precise structures recognized by these two antibodies were elucidated through enzyme-linked immunosorbent assay and immunostaining on thin-layer chromatography. One MAb, GMR8, which was generated by immunizing the mice with purified GM3(NeuGc), reacted specifically with gangliosides having NeuGc alpha 2----3Gal- terminal structures, such as GM3(NeuGc), IV3NeuGc alpha-Gg4Cer, IV3NeuGc alpha-nLc4Cer, V3NeuGc alpha-Gb5Cer, and GD1a(NeuGc, NeuGc). None of the other gangliosides having internal NeuGc alpha2----3Gal- sequences, such as GM2(NeuGc) and GM1(NeuGc), nor corresponding gangliosides having NeuAc alpha 2----3Gal- sequences, nor neutral glycolipids were recognized. Thus, the epitope structures recognized by the MAb were found to be strictly NeuGc alpha 2----3Gal- terminal structures. In contrast, the other MAb, GMR3, which was generated by immunizing the mice with purified GD3(NeuGc-NeuGc-) adsorbed to the bacteria, reacted specifically with gangliosides having NeuGc alpha 2----8NeuGc alpha 2----3Gal- terminal sequences, such as GD3(NeuGc-NeuGc-), IV3NeuGc alpha 2-Gg4Cer, IV3NeuGc alpha 2-nLc4Cer, and V3NeuGc alpha 2-Gb5Cer, but did not react with corresponding gangliosides having NeuAc as their sialic acid moiety or with the neutral glycolipids tested. The epitope structures recognized by the MAb were suggested to be NeuGc alpha 2----8NeuGc alpha 2----3Gal- terminal structures. Using these MAbs, we determined the distribution of such gangliosides in the spleen, kidney, and liver of several mice strains. Novel gangliosides reactive with these MAbs were detected in these tissues.
我们通过用吸附于明尼苏达沙门氏菌的这些纯化神经节苷脂免疫C3H/HeN小鼠,随后与小鼠骨髓瘤细胞融合,产生了两种分别对以N-羟乙酰神经氨酸(NeuGc)作为其唾液酸部分的单唾液酸和双唾液酸神经节苷脂具有特异性的小鼠单克隆抗体(MAb)。通过使用包括含NeuGc的神经节苷脂在内的多种糖脂,借助酶联免疫吸附测定和薄层色谱上的免疫染色,阐明了这两种抗体所识别的精确结构。一种单克隆抗体GMR8是通过用纯化的GM3(NeuGc)免疫小鼠产生的,它与具有NeuGcα2----3Gal末端结构的神经节苷脂特异性反应,如GM3(NeuGc)、IV3NeuGcα-Gg4Cer、IV3NeuGcα-nLc4Cer、V3NeuGcα-Gb5Cer和GD1a(NeuGc, NeuGc)。其他具有内部NeuGcα2----3Gal序列的神经节苷脂,如GM2(NeuGc)和GM1(NeuGc),以及具有NeuAcα2----3Gal序列的相应神经节苷脂和中性糖脂均未被识别。因此,发现该单克隆抗体所识别的表位结构严格为NeuGcα2----3Gal末端结构。相比之下,另一种单克隆抗体GMR3是通过用吸附于细菌的纯化GD3(NeuGc-NeuGc-)免疫小鼠产生的,它与具有NeuGcα2----8NeuGcα2----3Gal末端序列的神经节苷脂特异性反应,如GD3(NeuGc-NeuGc-)、IV3NeuGcα2-Gg4Cer、IV3NeuGcα2-nLc4Cer和V3NeuGcα2-Gb5Cer,但不与以NeuAc作为其唾液酸部分的相应神经节苷脂或所测试的中性糖脂反应。该单克隆抗体所识别的表位结构被认为是NeuGcα2----8NeuGcα2----3Gal末端结构。利用这些单克隆抗体,我们测定了几种小鼠品系的脾脏、肾脏和肝脏中此类神经节苷脂的分布。在这些组织中检测到了与这些单克隆抗体反应的新型神经节苷脂。